Migraine and Stroke

Deep Dive

From a Western clinical standpoint, migraine and stroke intersect through epidemiology, mechanisms, and management decisions. Large meta-analyse... From a Western clinical standpoint, migraine and stroke intersect through epidemiology, mechanisms, and management decisions. Large meta-analyses and nationwide cohorts consistently show that migraine with aura carries about a twofold increased relative risk of ischemic stroke, with the signal strongest in women younger than 45. The absolute risk in this age group remains low, but it is meaningfully modified by other exposures—most notably smoking and estrogen-containing contraceptives. The risk increment for hemorrhagic stroke is smaller and less consistent, observed primarily in women with active aura. Mechanistically, migraine is a neurovascular disorder. Cortical spreading depression (CSD)—a wave of neuronal and glial depolarization—underlies the aura and creates transient perfusion and metabolic mismatch. In parallel, evidence points to endothelial dysfunction, altered nitric oxide signaling, platelet activation, and a proinflammatory, prothrombotic milieu in some patients. PFO is more prevalent among those with aura and provides a conduit for paradoxical emboli, explaining cryptogenic events in a subset. Rarely, aura persists beyond 60 minutes with an infarct in the corresponding territory—termed migrainous infarction. Clinically, the first priority is accurate triage. Aura typically evolves gradually with positive symptoms (scintillations, paresthesias) that spread over minutes and may migrate between modalities, whereas TIA or stroke deficits often start abruptly, are negative (loss of function), and peak at onset. Yet features can overlap, so sudden new focal deficits, atypical or first/worst headaches, prolonged aura, motor weakness, or symptoms in pregnancy/postpartum warrant emergency stroke evaluation with imaging and neurology input. For prevention, clinicians focus on rigorous control of blood pressure, lipids, diabetes, and smoking cessation. In women with aura, guidelines advise careful selection of contraception, often favoring progestin-only or nonhormonal options in those with additional vascular risks. For acute migraine in patients with cerebrovascular disease or high risk, non-vasoconstrictive agents (ditans, gepants) are favored over triptans or ergots. Antiplatelet therapy is reserved for standard vascular indications rather than for migraine alone. Ongoing research is clarifying the long-term vascular safety of CGRP-pathway therapies and the clinical utility of PFO evaluation beyond cryptogenic stroke.